AMP-ROBOTICS
30.5.2022 08:02:04 CEST | Business Wire | Press release
AMP Robotics Corp. (“AMP”), a pioneer in AI, robotics, and infrastructure for the waste and recycling industry, continues to expand its presence in Europe to meet the demand for its AI and automation solutions and provide dedicated local support and service for the market. The company is exhibiting at IFAT 2022 , May 30-June 3 in Munich, for the first time.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220529005046/en/
AMP installed its first AI-guided robotics systems in the UK and Ireland with Recyco in September 2021 and has since deployed more recycling solutions throughout Europe, including at FCC Medio Ambiente/Environment in Spain. AMP has grown its team to include sales support, training, service, and marketing, in addition to direct sales staff focused on serving Austria, Belgium, France, Germany, Luxembourg, The Netherlands, and Switzerland, along with the UK and Ireland.
“AMP is the leading brand in robotics, and that was an important factor for us in choosing a solution to improve our sorting productivity and efficiency,” said Alfredo Vigre, project manager, Waste Treatment Department, FCC Medio Ambiente/Environment. “We tested the robot prior to implementation and were pleased with its ability to recognize and recover materials that optical sorters cannot. It’s been fast and effective, and a great tool for quality control.”
AMP provides a portfolio of recycling solutions powered by its industry-leading neural network, which is built on a data engine that has recognized more than 50 billion containers and packaging types in real-world conditions. AMP Cortex™ is the company’s high-speed robotic sorting system with approximately 230 deployments in more than 80 facilities across three continents. AMP’s install base is the largest known fleet of recycling robots in the world, creating the most expansive neural network of field data for recycled materials. AMP Vision™ is a modular computer vision system that helps operators understand material flow throughout key stages of sorting operations and serves as a quick and efficient alternative to manual sampling audits. When integrated with AMP Clarity™, the company’s material characterization and robot performance software solution, users can monitor real-time material characterization and performance measurement throughout a facility. AMP recently introduced new Clarity features including mass estimation; robot pick assignments, alerts, and status tracking; and expanded reporting capabilities.
“We’re seeing strong interest in and satisfaction with our AI and robotics technology here in Europe thanks to our technological leadership,” said Gary Ashburner, general manager, Europe, for AMP Robotics. “Our AI platform, AMP Neuron, continues to achieve breakthroughs in data accuracy and classification of different polymers, form factors, and other packaging types, which is helping our customers take a more data-driven approach to increasing recovery, lowering costs, and optimizing operations.”
At IFAT, AMP’s European-based team will provide live demonstrations of the company’s vision system for material characterization at booth 546 in Hall B6.
“As we continue to scale our business and innovate new ways to improve the economics of recycling, we’re committed to the European market and our growing customer base there,” said Matanya Horowitz, founder and CEO of AMP Robotics. “Our efforts to modernize Europe’s recycling infrastructure are important to our global investors, and critical to realizing our vision of a world without waste.”
About AMP Robotics® Corp.
AMP Robotics is modernizing the world’s recycling infrastructure by applying AI and automation to increase recycling rates and economically recover recyclables reclaimed as raw materials for the global supply chain. The AMP Cortex™ high-speed robotics system automates the identification and sorting of recyclables from mixed material streams. The AMP Neuron™ AI platform continuously trains itself by recognizing different colors, textures, shapes, sizes, patterns, and even brand labels to identify materials and their recyclability. Neuron then guides robots to pick and place the material to be recycled. Designed to run 24/7, all of this happens at superhuman speed with extremely high accuracy. AMP Clarity™ provides data and material characterization on what recyclables are captured and missed, helping recycling businesses and producers maximize recovery. With deployments across North America, Asia, and Europe, AMP’s technology recovers recyclables from municipal collection, precious commodities from electronic scrap, high-value materials from construction and demolition debris, and valuable feedstocks from organic material.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220529005046/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
